Evolving Treatment Landscape in Myelodysplastic Syndromes - Episode 5

Second-Line Treatment of Lower-Risk MDS With Symptomatic Anemia

, , ,

Continuing their discussion on the first patient profile, the expert panel focuses on the second-line treatment of patients with lower-risk MDS and symptomatic anemia.